Glaukos Corporation $GKOS Stock Position Cut by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC trimmed its stake in shares of Glaukos Corporation (NYSE:GKOS) by 4.9% during the first quarter, Holdings Channel reports. The institutional investor owned 124,951 shares of the medical instruments supplier’s stock after selling 6,453 shares during the period. Segall Bryant & Hamill LLC’s holdings in Glaukos were worth $13,452,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Horizon Corp boosted its stake in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 223 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Glaukos in the fourth quarter worth about $28,000. Larson Financial Group LLC lifted its holdings in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 215 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

GKOS opened at $166.52 on Friday. The firm has a market capitalization of $9.82 billion, a P/E ratio of -51.24 and a beta of 0.75. The stock has a fifty day moving average of $138.11 and a 200-day moving average of $125.07. The company has a quick ratio of 4.73, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $184.00.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.07. The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.Glaukos’s quarterly revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.24) earnings per share. Equities analysts forecast that Glaukos Corporation will post -0.41 EPS for the current fiscal year.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total value of $1,600,000.00. Following the completion of the sale, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at $7,024,960. This represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This represents a 12.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 40,000 shares of company stock worth $6,028,800 in the last quarter. 5.90% of the stock is owned by corporate insiders.

Trending Headlines about Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Quarterly results exceeded expectations. Glaukos reported second-quarter revenue of $185.6 million, up 49.6% year over year and well above the $150.9 million consensus estimate. Its adjusted loss of $0.14 per share was narrower than the expected $0.21 loss, supported by growth in iDose TR and Epioxa. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth
• Positive Sentiment: Management raised its 2026 outlook. Glaukos now expects net sales of $680 million to $700 million, with iDose TR revenue projected at $275 million to $280 million. The higher forecast signals continued commercial momentum and was a key reason the stock advanced. Glaukos outlines 2026 sales outlook
• Positive Sentiment: Clinical and analyst catalysts added support. The company reported progress on its PRESERFLO study, while BTIG raised its price target from $164 to $193 and maintained a Buy rating. BTIG raises Glaukos price target
• Neutral Sentiment: UBS Group initiated coverage of Glaukos, potentially broadening institutional attention, although the available report does not provide a detailed rating or price target. UBS initiates Glaukos coverage
• Negative Sentiment: Valuation and profitability remain risks. Despite the improved results, Glaukos remains unprofitable, and commentary questioned whether the stock’s strong rally has priced in much of its growth potential. Future gains may depend on continued iDose TR adoption and execution against the raised forecast. Glaukos record sales and valuation analysis

Analyst Ratings Changes

Several analysts recently commented on the stock. HC Wainwright increased their target price on shares of Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Friday, July 17th. Truist Financial upped their target price on Glaukos from $180.00 to $215.00 and gave the company a “buy” rating in a report on Thursday. Stifel Nicolaus increased their price target on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a report on Saturday. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and an average target price of $177.33.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.